Loading data for FHTX — first visit, this takes a few seconds.

알림

Foghorn Therapeutics Inc. (FHTX)

NasdaqGM: FHTX · 실시간 가격 · USD

6.87

+0.12 (1.78%)

종가 기준: Aug 19, 2026, 1:28 PM

1.78% (1D)

매수호가	3.55
시가총액	408.57M
매출 (ttm)	36.74M
순이익 (ttm)	-64.58M
베타	2.83
EPS (ttm)	-0.99
P/E (ttm)	n/a
선행 P/E	-6.69
P/B (ttm)	-4.99
P/S (ttm)	11.12
Earnings Date	Nov 5, 2026

매도호가	6.1
거래량	161,182
평균 거래량 (20일)	264,100
시가	6.94
전일 종가	6.75
일중 범위	6.78 - 7.17
52주 범위	3.27 - 7.17
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

FHTX 소개

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, o...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Oct 23, 2020

직원 수 106

상장 거래소 NasdaqGM

티커 FHTX

웹사이트 https://foghorntx.com

전체 기업 정보

재무 실적

2025년 Foghorn Therapeutics의 매출은 30.91M로, 전년 22.6M 대비 36.75% 증가했습니다. 순이익은 -74.28M로, -14.24% 감소했습니다.

재무제표

어닝 서프라이즈

Foghorn Therapeutics가 Aug 6, 2026에 분기 실적을 발표했습니다:

매출 $16.07M 예상치 하회 $0, 및 112.68% 전년 대비 성장.

EPS -0.1 예상치 상회 0.13, 및 64.29% 전년 대비 성장.

다음 실적 발표

Foghorn Therapeutics Inc.의 실적 발표 예정일은 Nov 5, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

5일 전 · Zacks

Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy

Does Foghorn Therapeutics Inc. (FHTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

1주 전 · Zacks

Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade

The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to an 88.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...

1주 전 · Zacks

Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Beats Revenue Estimates

Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of +56.52% and +98.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

3주 전 · Zacks

Acadia Healthcare (ACHC) Surpasses Q2 Earnings and Revenue Estimates

Acadia Healthcare (ACHC) delivered earnings and revenue surprises of +15.15% and +2.50%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1개월 전 · Zacks

Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains?

Foghorn Therapeutics (FHTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price...

2 페이지 중 1

Foghorn Therapeutics Inc. (FHTX)